Agendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer

Agendia, Inc. announced the first patient has been enrolled in the PROOFS Registry trial. The study aims to determine whether premenopausal women with early HR+ breast cancer can avoid chemotherapy, and maintain strong outcomes by opting instead for temporary ovarian function suppression in combination with endocrine therapy.